Acta Cytol

1. SHINOMIYA Y, Kouchi Y, Onodera K, Yamamoto H, et al
   Imprint Cytology of Tall Cell Carcinoma with Reversed Polarity of the Breast: A Case Report.
   Acta Cytol. 2024;68:73-79.
   

   >> Share

   
   
2. LI JJX, Chow MBCY, Ng JKM, Tsang JY, et al
   Cytomorphological Assessment in Aspirates of Ductal Carcinoma in situ: Correlations with Histopathologic Grade, Architectural Pattern, and Invasion.
   Acta Cytol. 2024;68:45-53.
   

   >> Share

   
   

   
   Am J Surg

3. WIENER AA, Neuman HB
   Improving shared decision making in virtual breast cancer surgery consultations.
   Am J Surg. 2023;225:645-649.
   

   >> Share

   
   

   
   Ann Surg

4. LI W, Huang YH, Zhu T, Zhang YM, et al
   Noninvasive Artificial Intelligence System for Early Predicting Residual Cancer Burden during Neoadjuvant Chemotherapy in Breast Cancer.
   Ann Surg. 2024 Apr 1. doi: 10.1097/SLA.0000000000006279.
   

   >> Share

   
   

   
   Ann Surg Oncol

5. WIENER AA, Schumacher JR, Perlman SB, Wilke LG, et al
   A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer.
   Ann Surg Oncol. 2024 Apr 1. doi: 10.1245/s10434-024-15235.
   

   >> Share

   
   

   
   BMC Cancer

6. LI B, Dai S, Wang Q, Jing H, et al
   Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.
   BMC Cancer. 2024;24:409.
   

   >> Share

   
   
7. WU Z, Zhang Q, Jin Y, Zhang X, et al
   Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
   BMC Cancer. 2024;24:411.
   

   >> Share

   
   
8. QIU C, Wang W, Xu S, Li Y, et al
   Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer.
   BMC Cancer. 2024;24:402.
   

   >> Share

   
   

   
   Breast Cancer

9. YOSHIMURA M, Yamauchi C, Sanuki N, Hamamoto Y, et al
   The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.
   Breast Cancer. 2024 Apr 5. doi: 10.1007/s12282-024-01568.
   

   >> Share

   
   
10. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 Apr 3. doi: 10.1007/s12282-024-01566.
    

    >> Share

    
    
11. OCHIYA T, Hashimoto K, Shimomura A
    Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer.
    Breast Cancer. 2024 Mar 30. doi: 10.1007/s12282-024-01563.
    

    >> Share

    
    
12. YE JH, Yu J, Huang MY, Mo YM, et al
    The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Breast Cancer. 2024 Apr 1. doi: 10.1007/s12282-024-01553.
    

    >> Share

    
    
13. LIN D, Sturgeon KM, Muscat JE, Zhou S, et al
    Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
    Breast Cancer. 2024 Apr 2. doi: 10.1007/s12282-024-01569.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

14. UBOWSKI MM, VanSice R, Marriott M, Yacobucci MJ, et al
    Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:149-162.
    

    >> Share

    
    
15. NOBBE K, Erices-Leclercq M, Foerster F, Forster R, et al
    HER2 Low Expression in Primary Male Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:141-148.
    

    >> Share

    
    

    
    Breast Cancer Res

16. SAFAEI S, Fadaee M, Farzam OR, Yari A, et al
    Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.
    Breast Cancer Res. 2024;26:57.
    

    >> Share

    
    
17. CHI F, Griffiths JI, Nath A, Bild AH, et al
    Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Breast Cancer Res. 2024;26:54.
    

    >> Share

    
    
18. OLIPHANT MUJ, Akshinthala D, Muthuswamy SK
    Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer.
    Breast Cancer Res. 2024;26:56.
    

    >> Share

    
    
19. BASHARI MH, Fan F, Vallet S, Sattler M, et al
    Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
    Breast Cancer Res. 2024;26:58.
    

    >> Share

    
    
20. WALLACE G, Kundalia R, Vallebuona E, Cao B, et al
    Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Breast Cancer Res. 2024;26:55.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

21. BURO AW, Nguyen T, Abaskaron M, Haver MK, et al
    Lifestyle interventions with dietary strategies after breast cancer diagnosis: a systematic review.
    Breast Cancer Res Treat. 2024 Mar 29. doi: 10.1007/s10549-024-07278.
    

    >> Share

    
    
22. CAMPBELL EK, Campbell TM, Culakova E, Blanchard L, et al
    A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
    Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284.
    

    >> Share

    
    
23. MARTINEZ-JANEZ N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, et al
    First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.
    Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07287.
    

    >> Share

    
    
24. BLOMQVIST C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, et al
    Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study.
    Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07252.
    

    >> Share

    
    
25. YERUSHALMI R, Pomerantz A, Lewin R, Paluch-Shimon S, et al
    BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
    Breast Cancer Res Treat. 2024 Apr 3. doi: 10.1007/s10549-024-07271.
    

    >> Share

    
    
26. ALHUDIRI I, Nolan C, Ellis I, Elzagheid A, et al
    Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.
    Breast Cancer Res Treat. 2024 Apr 5. doi: 10.1007/s10549-024-07293.
    

    >> Share

    
    
27. SULLIVAN M, Lei X, Giordano SH, Chavez-MacGregor M, et al
    Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis.
    Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07301.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

28. MOSS JL, Geyer NR, Lengerich EJ
    Patterns of Cancer-Related Healthcare Access across Pennsylvania: Analysis of Novel Census Tract-Level Indicators of Persistent Poverty.
    Cancer Epidemiol Biomarkers Prev. 2024;33:616-623.
    

    >> Share

    
    
29. BARBER LE, McCullough LE, Johnson DA
    Eyes Wide Open: Sleep as a Potential Contributor to Racial and Ethnic Disparities in Cancer.
    Cancer Epidemiol Biomarkers Prev. 2024;33:471-479.
    

    >> Share

    
    
30. HAN E, Van Horn L, Snetselaar L, Shepherd JA, et al
    The Associations between Intakes of One-Carbon Metabolism-Related Vitamins and Breast Density among Young Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:567-575.
    

    >> Share

    
    

    
    Cancer Lett

31. ORHAN E, Velazquez C, Tabet I, Fenou L, et al
    CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820.
    

    >> Share

    
    
32. YANG Z, Chen H, Yin S, Mo H, et al
    PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
    Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795.
    

    >> Share

    
    

    
    Clin Breast Cancer

33. JIA X, Wang K, Zhuo Q, Zhao Z, et al
    PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Clin Breast Cancer. 2024 Mar 2:S1526-8209(24)00059.
    

    >> Share

    
    
34. CAKIT BD, Vural SP
    Short-Term Effects Of Dry Heat Treatment (Fluidotherapy) In The Management Of Breast Cancer Related Lymphedema: A Randomized Controlled Study.
    Clin Breast Cancer. 2024 Mar 1:S1526-8209(24)00056.
    

    >> Share

    
    
35. BA ZC, Zhang HX, Liu AY, Zhou XX, et al
    Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes.
    Clin Breast Cancer. 2024 Mar 13:S1526-8209(24)00079.
    

    >> Share

    
    
36. WEN W, Li Y, Cao X, Li Y, et al
    Expression and Clinical Significance of NUDCD1, PI3K/AKT/mTOR Signaling Pathway-Related Molecules and Immune Infiltration in Breast Cancer.
    Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00060.
    

    >> Share

    
    
37. HUANG JX, Chen YJ, Wang XY, Huang JH, et al
    Nomogram Based on US and Clinicopathologic Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer.
    Clin Breast Cancer. 2024 Mar 13:S1526-8209(24)00078.
    

    >> Share

    
    

    
    Clin Cancer Res

38. CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al
    Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
    Clin Cancer Res. 2024;30:1273-1280.
    

    >> Share

    
    
39. HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al
    The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526.
    

    >> Share

    
    
40. MOYER CL, Lanier A, Qian J, Coleman D, et al
    IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
    Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839.
    

    >> Share

    
    

    
    Discov Oncol

41. SAYED ZS, Khattap MG, Madkour MA, Yasen NS, et al
    Circulating tumor cells clusters and their role in Breast cancer metastasis; a review of literature.
    Discov Oncol. 2024;15:94.
    

    >> Share

    
    
42. SUZUKI T, Nakanishi Y, Tanino T, Nishimaki-Watanabe H, et al
    Immunohistochemical and molecular profiles of heterogeneous components of metaplastic breast cancer: a squamous cell carcinomatous component was distinct from a spindle cell carcinomatous component.
    Discov Oncol. 2024;15:95.
    

    >> Share

    
    

    
    Eur J Cancer

43. ROUSSOT N, Constantin G, Desmoulins I, Bergeron A, et al
    Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2024;202:114037.
    

    >> Share

    
    

    
    Eur J Surg Oncol

44. SAE-LIM C, Lai HW, Lin SL, Huang HI, et al
    Is minimal-accessed (endoscopic- or robotic-assisted) nipple-sparing mastectomy contraindicated for large breasts?
    Eur J Surg Oncol. 2024;50:108030.
    

    >> Share

    
    
45. MEATTINI I, Kunkler IH
    Omission of radiation therapy after breast conserving surgery for older women at low-risk of local recurrence: One option among many.
    Eur J Surg Oncol. 2024;50:108058.
    

    >> Share

    
    
46. NAVARRO AS, Omalek D, Chaltiel L, Vaysse C, et al
    Oncologic safety of autologous fat grafting in primary breast reconstruction after mastectomy for cancer.
    Eur J Surg Oncol. 2024;50:107998.
    

    >> Share

    
    

    
    Histopathology

47. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    

    >> Share

    
    

    
    Int J Cancer

48. LIN YY, Gao HF, Li H, Hu Q, et al
    Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
    

    >> Share

    
    
49. WANG Y, Cai W, He P, Cai Q, et al
    Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
    

    >> Share

    
    
50. 
    Correction to "Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database".
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34925.
    

    >> Share

    
    
51. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

52. KHAN AJ, Marine CB, Flynn J, Tyagi N, et al
    A Phase II Study Evaluating the Effect of Intensity-Modulated Post-Mastectomy Radiation Therapy on Implant Failure Rates in Breast Cancer Patients with Immediate, 2-Stage Implant Reconstruction, with an MRI imaging correlative substudy.
    Int J Radiat Oncol Biol Phys. 2024 Apr 1:S0360-3016(24)00451.
    

    >> Share

    
    

    
    J Clin Oncol

53. VALENZA C, Trapani D, Loibl S, Chia SKL, et al
    Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
    J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935.
    

    >> Share

    
    
54. MUTTER RW, Chauhan C, Goetz MP, Wright JL, et al
    Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens.
    J Clin Oncol. 2024 Apr 2:JCO2302289. doi: 10.1200/JCO.23.02289.
    

    >> Share

    
    

    
    J Natl Cancer Inst

55. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
    TP53-associated early breast cancer: new observations from a large cohort.
    J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

56. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    

    >> Share

    
    
57. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    

    >> Share

    
    
58. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    

    >> Share

    
    

    
    J Surg Oncol

59. NTOWE KW, Lee MS, Plichta JK
    Clinical genetics in breast cancer.
    J Surg Oncol. 2024 Apr 1. doi: 10.1002/jso.27630.
    

    >> Share

    
    
60. SPIEKERMAN VAN WEEZELENBURG MA, de Rooij L, Aldenhoven L, van Kuijk SMJ, et al
    Drain-free mastectomy and flap fixation: The interim analysis of a randomized controlled noninferiority trial.
    J Surg Oncol. 2024;129:975-980.
    

    >> Share

    
    

    
    JAMA

61. LEON-FERRE RA, Jonas SF, Salgado R, Loi S, et al
    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    JAMA. 2024;331:1135-1144.
    

    >> Share

    
    

    
    Lancet

62. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    

    >> Share

    
    
63. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    

    >> Share

    
    

    
    NPJ Breast Cancer

64. LEON-FERRE RA, Carter JM, Zahrieh D, Sinnwell JP, et al
    Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:25.
    

    >> Share

    
    
65. TARANTINO P, Leone J, Vallejo CT, Freedman RA, et al
    Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:26.
    

    >> Share

    
    

    
    Oncogene

66. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
    Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
    Oncogene. 2024;43:1063-1074.
    

    >> Share

    
    
67. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
    Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
    Oncogene. 2024 Apr 5. doi: 10.1038/s41388-024-03023.
    

    >> Share

    
    

    
    Pathology

68. WU Y, Chen F, Pan L, Chao X, et al
    Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
    Pathology. 2024 Mar 14:S0031-3025(24)00084-9. doi: 10.1016/j.pathol.2024.
    

    >> Share

    
    

    
    PLoS One

69. KANG ES, Lim YC, Jang BH, Lee YJ, et al
    Changes in lymph node surgery in breast cancer and preoperative drug prescription analysis for postoperative pain management: A retrospective, cross-sectional study.
    PLoS One. 2024;19:e0298270.
    

    >> Share

    
    
70. FONSECA-ALVES CE, Leis-Filho AF, Lacerda ZA, de Faria Lainetti P, et al
    Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    PLoS One. 2024;19:e0297043.
    

    >> Share

    
    
71. ZHU K, Sui Y, Zhu M, Gao Y, et al
    Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study.
    PLoS One. 2024;19:e0301057.
    

    >> Share

    
    

    
    Radiol Artif Intell

72. PARK EK, Kwak S, Lee W, Choi JS, et al
    Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time.
    Radiol Artif Intell. 2024 Apr 3:e230318. doi: 10.1148/ryai.230318.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

73. DIWANJI D, Onishi N, Hathi DK, Lawhn-Heath C, et al
    (18)F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
    Radiol Imaging Cancer. 2024;6:e230082.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share